Format

Send to

Choose Destination
Clin Pharmacol Ther. 2013 Sep;94(3):367-75. doi: 10.1038/clpt.2013.99. Epub 2013 May 13.

Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis.

Author information

1
Pharmaceutical Sciences Postgraduate Course, University of Sorocaba, UNISO, Sorocaba, Brazil. luslopes@terra.com.br

Abstract

Vitamin K antagonists (VKAs) prevent stroke in atrial fibrillation (AF) at the cost of bleeding risk. To determine major bleeding rates in AF patients, we conducted a systematic review that identified 51 eligible studies including more than 342,699 patients. The pooled estimate of the rate of major bleeding was 2.51 (99% confidence interval: 2.03-3.11) bleeds per 100 patient-years. The results represent the best estimates of bleeding risk that most patients contemplating VKA use may expect.

PMID:
23670121
DOI:
10.1038/clpt.2013.99
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center